LDZU Stock Chart & Stats
€8.35
-€0.05(-0.65%)
At close: 4:00 PM EDT
€8.35
-€0.05(-0.65%)
Day’s Range― - ―
52-Week Range€4.26 - €8.40
Previous CloseN/A
Volume0.00
Average Volume (3M)8.00
Market Cap
€3.72B
Enterprise Value€4.78K
Total Cash (Recent Filing)€15.87B
Total Debt (Recent Filing)€15.44B
Price to Earnings (P/E)26.3
Beta0.40
Next Earnings
Mar 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.87
Shares Outstanding446,252,320
10 Day Avg. Volume0
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)0.86
Price to Sales (P/S)2.00
P/FCF Ratio14.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.6
Revenue Forecast (FY)€1.99B
Bulls Say, Bears Say
Bulls Say
Commercial Pharma Growth And Margin ExpansionCommercial Pharma is showing broad-based growth and operating leverage across injectables, prescription medicines, and OTC products. This stronger mix and 29.2% EBITDA margin can provide a more durable earnings foundation while manufacturing operations recover.
Improving Free Cash Flow GenerationThe sharp improvement in operating cash flow and free cash flow demonstrates better cash earnings, supported by lower working capital, reduced finance costs, and lower capital expenditure. Sustained cash generation would improve debt service capacity and fund strategic priorities.
Potential Material Debt Reduction From APAC DivestmentThe planned APAC divestment could materially strengthen Aspen’s balance sheet if completed on the stated terms. Applying proceeds to debt would reduce interest costs and leverage, giving management greater flexibility to invest in commercial growth and operational recovery.
Bears Say
Manufacturing Performance Has Deteriorated SharplyThe lost mRNA contract and related settlement caused a substantial adverse EBITDA swing, exposing the earnings sensitivity of Aspen’s manufacturing platform to contract concentration and execution. Replacing that contribution will be necessary for a durable group recovery.
Group Revenue, Earnings, And Margins Remain Under PressureThe decline in revenue, earnings, and gross margin shows that the commercial business has not yet offset manufacturing and steriles weakness. Lower profitability than in prior years reduces earnings resilience and makes the recovery plan dependent on sustained execution.
Sterile Business Losses And Weak Returns Require RecoveryLosses in the sterile business directly weigh on consolidated profitability and indicate that parts of the manufacturing footprint are not yet earning attractive returns. Restructuring and new contracts must reach the FY27 breakeven target before this segment becomes a durable contributor.
Aspen Pharmacare News
LDZU FAQ
What was Aspen Pharmacare’s price range in the past 12 months?
Aspen Pharmacare lowest stock price was €4.26 and its highest was €8.40 in the past 12 months.
What is Aspen Pharmacare’s market cap?
Aspen Pharmacare’s market cap is €3.72B.
When is Aspen Pharmacare’s upcoming earnings report date?
Aspen Pharmacare’s upcoming earnings report date is Mar 11, 2027 which is in 180 days.
How were Aspen Pharmacare’s earnings last quarter?
Aspen Pharmacare released its earnings results on Sep 02, 2026. The company reported €0.139 earnings per share for the quarter.
Is Aspen Pharmacare overvalued?
According to Wall Street analysts Aspen Pharmacare’s price is currently Overvalued.
Does Aspen Pharmacare pay dividends?
Aspen Pharmacare does not currently pay dividends.
What is Aspen Pharmacare’s EPS estimate?
Aspen Pharmacare’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aspen Pharmacare have?
Aspen Pharmacare has 446,252,320 shares outstanding.
What happened to Aspen Pharmacare’s price movement after its last earnings report?
Aspen Pharmacare reported an EPS of €0.139 in its last earnings report. Following the earnings report the stock price went down -0.606%.
Which hedge fund is a major shareholder of Aspen Pharmacare?
Currently, no hedge funds are holding shares in DE:LDZU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aspen Pharmacare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.66%
12-Months-Change
Fundamentals
Return on Equity
1.14%
Trailing 12-Months
Asset Growth
-13.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aspen Pharmacare
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon, and Xylocaine brands; over-the-counter medicines under the Emla, Maltofer, Ovestin, Solpadeine, and Xylocaine brands; and prescription products for anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids under the Eltroxin, Imuran, Lipitor, Lyrica, and Zyloric brands. It also manufactures active pharmaceutical ingredients, finished dose forms, and heparins, as well as steriles, oral solid doses, liquids, semi-solids, and biologicals. The company exports its products. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.
LDZU Company Deck
LDZU Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveys a balanced picture: strong operational cash generation, clear commercial pharma momentum (notably GLP‑1 traction), and a material APAC divestment that should materially strengthen the balance sheet and unlock shareholder value. Offsetting these positives are significant near‑term manufacturing and sterile segment setbacks (large EBITDA and revenue hits from lost contracts), a meaningful short‑term decline in group earnings, and ongoing macro/regulatory and currency risk. Management presented a defined recovery plan (cost reshaping, contract commercialization, insulin ramp, French site wins and sterile restructuring) and targets FY27 restoration of prior EBITDA levels, but execution is required to convert the improvements signaled into sustainable results.View all DE:LDZU earnings summariesTechnical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Alvotech
―